Indication

Squamous cell carcinoma of the anal canal

Squamous cell carcinoma of the anal canal is a malignant epithelial neoplasm arising from the mucosal lining of the lower gastrointestinal tract between the anorectal junction and the anal verge. Read more about Squamous cell carcinoma of the anal canal

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Squamous cell carcinoma of the anal canal therapies.

Showing 1–1 of 1 drugs

ZYNYZ (retifanlimab-dlwr)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MERKEL CELL CARCINOMA·+1
Incyte Corporation
Filter & compare in the drug finder →Opens the drug finder with Squamous cell carcinoma of the anal canal preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Squamous cell carcinoma of the anal canal.

Squamous cell carcinoma of the anal canal is a malignant epithelial neoplasm arising from the mucosal lining of the lower gastrointestinal tract between the anorectal junction and the anal verge.

It represents the vast majority of primary anal malignancies, predominantly driven by high-risk oncogenic human papillomavirus infection—particularly types 16 and 18—with elevated risk among individuals who are immunocompromised, living with HIV, or active smokers.

Pathophysiologically, persistent viral oncoprotein activity leads to dysplastic squamous changes that progress into invasive carcinoma, commonly manifesting clinically with rectal bleeding, anal pain, a palpable mass, pruritus, or altered bowel habits.

Personalize your experience

Follow Squamous cell carcinoma of the anal canal and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it